Future studies should investigate whether FLT3 activation cooperates with epigenetic dysregulation in ALL, which might suggest a potential use for combination treatment using FLT3 inhibitors with epigenetic therapies, as recently proposed for AML [54]. The gene discussed is FLT3; the disease is acute myeloid leukemia.